Therapeutic use of erythropoietin in dermatooncology

J Dtsch Dermatol Ges. 2007 Apr;5(4):280-5. doi: 10.1111/j.1610-0387.2007.06203.x.
[Article in English, German]

Abstract

Erythropoietin has been successfully used in Europe since 1997 in the treatment of anemia induced by chemotherapy of solid tumors. There is only limited experience with regard to its use when treating dermatologic tumors such as metastatic melanoma. We review here current guidelines on the use of erythropoietin in cancer patients and report on our own melanoma patients treated with erythropoietin for chemotherapy-induced anemia.

Publication types

  • Review

MeSH terms

  • Anemia / chemically induced*
  • Anemia / drug therapy*
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Dermatology / methods
  • Dermatology / standards
  • Dermatology / trends
  • Erythropoietin / therapeutic use*
  • Humans
  • Medical Oncology / methods
  • Medical Oncology / standards
  • Medical Oncology / trends
  • Practice Guidelines as Topic*
  • Practice Patterns, Physicians' / trends
  • Skin Neoplasms / complications
  • Skin Neoplasms / drug therapy

Substances

  • Antineoplastic Agents
  • Erythropoietin